Literature DB >> 25792894

Isokinetic trunk and knee muscle strengths and gait performance in walking patients with T-cell lymphotropic virus type 1-associated myelopathy/ tropical spastic paraparesis (HAM/TSP).

Masashi Miyazaki1, Harutoshi Sakakima1, Tatsushi Goto1, Ryoji Kiyama1, Toshio Matsuzaki2, Kosei Ijiri3, Yoshihiro Yoshida1.   

Abstract

The aim of this study was to investigate the isokinetic trunk and knee muscle strengths, and examine the clinical relevance of dynamic muscle strengths and gait performance in walking patients with human T-cell lymphotropic virus type 1-associated myelopathy/ tropical spastic paraparesis (HAM/TSP). Thirteen patients with HAM/TSP (8 females and 5 males, aged 38-76) and 13 sex- and age-matched healthy control subjects participated in the study. We assessed gait speed, stride length, cadence; and maximal isokinetic torque of trunk and knee extensors and flexors at 30°/s, 60°/s and 90°/s using a Biodex System 3 dynamometer. Furthermore, we calculated the isokinetic trunk extensor/flexor (E/F) and hamstrings/quadriceps (H/Q) strength ratios (parameter of the muscle strength balance about the trunk and knee joint). Compared with the age-matched controls, the patients with HAM/TSP had significantly reduced gait speed, stride length and cadence (P < 0.05). Peak torque values related to body weight (PTBW) were significantly reduced, especially for the knee flexors (P < 0.05). For the knee extensors, the PTBW values were significantly reduced at an increased angular velocity (P < 0.05). The PTBW of knee flexors was positively correlated with gait speed and cadence in the patients with HAM/TSP. The H/Q ratio but not E/F ratio was significantly decreased compared with the control. Our results indicated that the isokinetic trunk and knee muscle performance had reduced from the ambulatory stage, and suggested the deterioration in knee muscle performance to be associated with gait disturbance in walking HAM/TSP patients.

Entities:  

Keywords:  HAM/TSP; agonist/antagonist ratio; isokinetic muscle strength; muscle weakness

Year:  2011        PMID: 25792894      PMCID: PMC4316538          DOI: 10.1298/jjpta.Vol14_003

Source DB:  PubMed          Journal:  J Jpn Phys Ther Assoc        ISSN: 1344-1272


  23 in total

1.  HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings.

Authors:  M Nakagawa; S Izumo; S Ijichi; H Kubota; K Arimura; M Kawabata; M Osame
Journal:  J Neurovirol       Date:  1995-03       Impact factor: 2.643

2.  HTLV-1 associated myelopathy (HAM).

Authors:  M Osame; A Igata; M Matsumoto; S Izumo; K Usuku; R L Rosales; M Tara
Journal:  Kansenshogaku Zasshi       Date:  1988-03

3.  HTLV-I associated myelopathy, a new clinical entity.

Authors:  M Osame; K Usuku; S Izumo; N Ijichi; H Amitani; A Igata; M Matsumoto; M Tara
Journal:  Lancet       Date:  1986-05-03       Impact factor: 79.321

4.  Knee muscle isometric strength, voluntary activation and antagonist co-contraction in the first six months after stroke.

Authors:  D J Newham; S F Hsiao
Journal:  Disabil Rehabil       Date:  2001-06-15       Impact factor: 3.033

5.  Reciprocal Ia inhibition in spastic hemiplegia of man.

Authors:  N Yanagisawa; R Tanaka; Z Ito
Journal:  Brain       Date:  1976-09       Impact factor: 13.501

6.  Disability profile of patients with HTLV-I-associated myelopathy/tropical spastic paraparesis using the Functional Independence Measure (FIM).

Authors:  A C Franzoi; A Q C Araújo
Journal:  Spinal Cord       Date:  2005-04       Impact factor: 2.772

7.  Natural history of human T-lymphotropic virus 1-associated myelopathy: a 14-year follow-up study.

Authors:  Stéphane Olindo; Philippe Cabre; Agnes Lézin; Harold Merle; Martine Saint-Vil; Aissatou Signate; Mickael Bonnan; Aurelie Chalon; Lionel Magnani; Raymond Cesaire; Didier Smadja
Journal:  Arch Neurol       Date:  2006-11

8.  Natural course of voiding function in patients with human T-cell lymphotrophic virus type 1-associated myelopathy.

Authors:  Ken-ichi Mori; Mitsuru Noguchi; Manabu Matsuo; Koichiro Nomata; Tatsufumi Nakamura; Hiroshi Kanetake
Journal:  J Neurol Sci       Date:  2004-01-15       Impact factor: 3.181

Review 9.  An HTLV-I vaccine: why, how, for whom?

Authors:  G de Thé; R Bomford
Journal:  AIDS Res Hum Retroviruses       Date:  1993-05       Impact factor: 2.205

Review 10.  Human T cell leukemia virus type I infection and chronic myelopathy.

Authors:  Y Iwasaki
Journal:  Brain Pathol       Date:  1993-01       Impact factor: 6.508

View more
  1 in total

1.  Incomplete myelopathy and human T cell lymphotropic virus type-1 (HTLV-1).

Authors:  Roberta Vilela Lopes Koyama; Gilberto Toshimitsu Yoshikawa; Satomi Fujihara; George Alberto da Silva Dias; Rodrigo Rodrigues Virgolino; Anderson Raiol Rodrigues; Rita Medeiros; Juarez Antônio Simões Quaresma; Hellen Thaís Fuzii
Journal:  J Neurovirol       Date:  2018-10-05       Impact factor: 2.643

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.